The Hepatology and Infectious Diseases Sections of the Chinese Medical Association organized experts in China to develop the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (1st edition) in 2005, and revised them for the first time in 2010. In the past 5 years
In the past five years, the basic and clinical research on chronic hepatitis B at home and abroad has made great progress, so we are revising this guideline again. The guidelines are intended to help clinicians make rational decisions in the diagnosis, prevention, and antiviral treatment of chronic hepatitis B. They are not mandatory standards and cannot include or address all issues in the diagnosis and treatment of chronic hepatitis B. Therefore, when faced with a particular patient, clinicians should develop a comprehensive and reasonable treatment plan based on their professional knowledge, clinical experience and available medical resources, with full knowledge of the best clinical evidence about the disease and careful consideration of the patient’s specific condition and his or her wishes. We will continue to update and improve this guideline in accordance with relevant advances at home and abroad. For patients receiving liver transplantation for HBV-related diseases, early use of HBV inhibitors is recommended.
Nucleoside (acid) analogs with strong effects and low incidence of drug resistance are recommended for early treatment to obtain the lowest possible viral load and prevent reinfection of the transplanted liver. Pediatric patients Pediatric HBV
infected patients are often in the immune tolerance phase and are usually not considered for antiviral therapy. In children with progressive liver disease or cirrhosis, antiviral therapy should be promptly administered, but long-term treatment safety and drug resistance need to be considered.